AA
ONC

AlphaCentric Advisors’s BeOne Medicines Ltd ONC Stock Holding History

AlphaCentric Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,500
Closed -$1.23M – 290
2024
Q3 		$1.23M Sell
5,500
-9,500
-63% -$1.71M 0.92% 35
2024
Q2 		$2.14M Sell
15,000
-1,750
-10% -$270K 1.58% 13
2024
Q1 		$2.62M Buy
16,750
+9,250
+123% +$1.49M 1.58% 12
2023
Q4 		$1.35M Buy
+7,500
New +$1.36M 0.91% 39

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AlphaCentric Advisors's ONC Position: Q4 2024 in Review

AlphaCentric Advisors sold out of BeOne Medicines Ltd (ONC) in Q4 2024, closing a stake of 5,500 shares — an estimated $1.23M sold.

AlphaCentric Advisors first reported a position in ONC in Q4 2023 and held it in 4 quarters. The position peaked at $2.62M in Q1 2024. 228 funds tracked by Wall St. Rank hold ONC as of Q4 2024.

  • AlphaCentric Advisors reported no remaining BeOne Medicines Ltd position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 5,500 BeOne Medicines Ltd shares in Q4 2024, an estimated $1.23M.
  • AlphaCentric Advisors first reported a position in BeOne Medicines Ltd in Q4 2023 and held it in 4 quarters.
  • AlphaCentric Advisors's BeOne Medicines Ltd position peaked at $2.62M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.